DiscoveryBioMed, Inc. (DBM) specializes in human cell engineering and human cell-based drug discovery.

- Custom human cell-based drug discovery

- Custom primary culture or immortal cell line creation

- Internal R&D programs in respiratory, metabolic, inflammatory and hyperproliferative diseases.

- "Human body in a microtiter plate" assessment of safety versus toxicity of panels of lead compounds in human skin, lung, liver, kidney and other in vivo-like human cells.

- Secondary and tertiary validation and mechanism of action analysis with human cell systems.

Please inquire to Dr. Erik Schwiebert, Ph.D., Director of DBM, Inc. concerning need for our services in cell engineering and/or cell-based drug discovery. Our process accelerates and streamlines the drug discovery process. Key ingredients to our process include implementing human cell platforms, designing primary and validation bioassays around revelant cell systems, screening each small molecule in triplicate, and making frequent cheminformatic 'peeks' at validated hits.

DBM operates in Innovation Depot, a state-of-the-art entrepreneurial center opened in 2007 through a partnership between the University of Alabama at Birmingham and other investors in the Birmingham area.

DBM has a client and partner base in 12 states and overseas and has made significant advances of late in its drug discovery programs.